TRENTON, N.J. (AP) -- New research shows a promising drug for
advanced lung tumors with a certain genetic mutation appears to
double survival over standard cancer drugs.
The drug from Pfizer Inc., called crizotinib, would be the first
targeted treatment for the roughly 50,000 people who get this
cancer each year worldwide. It might eventually produce annual
sales above $2 billion.
The first overall survival data for patients with advanced
non-small cell lung cancer treated with the drug shows 74 percent
were still alive after a year, and 54 percent after two years.
Researchers were announcing the findings at a cancer specialists
The drug is part of the new wave of personalized medicine in
which drugs are being matched to patients according to genetics.